Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study

Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study

<p>Abstract</p> <p>Background</p> <p>In August 2002, the antifungal prophylaxis algorithm for neutropenic hematology/oncology (NHO) patients at the Medical Center was changed from conventional amphotericin (AMB) to an azole (AZ) based regimen (fluconazole [FLU] in low-r...

Full description

Bibliographic Details
Main Authors:	Martin Thomas, Yuen Courtney, Inciardi John, Choe Lan, Riedel Amy, Guglielmo B Joseph
Format:	Article
Language:	English
Published:	BMC 2007-07-01
Series:	BMC Infectious Diseases
Online Access:	http://www.biomedcentral.com/1471-2334/7/70

Similar Items

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
by: Innocenti R, et al.
Published: (2018-12-01)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
by: Otremba B, et al.
Published: (2018-10-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
by: Innocenti R, et al.
Published: (2019-02-01)

Prophylaxis of Invasive Fungal Infection in Patients with Neutropenia Related to Chemotherapy or Hematologic Stem Cell Transplantation
by: Ya-Lien Huang, et al.
Published: (2012)

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
by: Stevenson Matt D, et al.
Published: (2011-09-01)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
by: Ricardo Fernandes, et al.
Published: (2017-04-01)

Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)

A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre
by: Karl Verpoort MD, et al.
Published: (2012-11-01)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
by: Esse I. H. Akpo, et al.
Published: (2017-09-01)

Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
by: Peterson Josh F, et al.
Published: (2006-12-01)

ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
by: Lourdes Vazquez
Published: (2016-09-01)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
by: Hoggatt J, et al.
Published: (2015-04-01)

Efficacy of using trimethoprim‐sulfamethoxazole prophylaxis in an adult patient with autoimmune neutropenia
by: Naoto Azuma, et al.
Published: (2019-09-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016-01-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
by: Hoggatt J, et al.
Published: (2015-08-01)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
by: Bhanu Vakkalanka, et al.
Published: (2011-01-01)

Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
by: Vineet Talwar, et al.
Published: (2017-01-01)

Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
by: Paola Villafuerte-Gutierrez, et al.
Published: (2014-01-01)

Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
by: Giovanni Rosti, et al.
Published: (2011-09-01)

Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis
by: Chong Y, et al.
Published: (2017-06-01)

Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study
by: Stefan Hatzl, et al.
Published: (2021-09-01)

Microbial translocation contribute to febrile episodes in adults with chemotherapy-induced neutropenia.
by: Michelle Wong, et al.
Published: (2013-01-01)

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
by: Jean-Pierre Gangneux, et al.
Published: (2020-11-01)

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
by: Edward Li, et al.
Published: (2021-06-01)

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
by: Edward Li, et al.
Published: (2021-06-01)

Corrigendum to “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update”
by: Paola Villafuerte-Gutierrez, et al.
Published: (2019-01-01)

Fluoroquinolone Prophylaxis Against Febrile Neutropenia in Areas With High Fluoroquinolone Resistance—An Asian Perspective
by: Esther Shu-Ting Ng, et al.
Published: (2010-09-01)

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz
by: McBride, Ali, et al.
Published: (2017)

Role of Biochemical Inflammatory Markers in Patients with Chemotherapy-Induced Neutropenia
by: YuN Dubinina, et al.
Published: (2019-09-01)

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
by: Talita Garcia do Nascimento, et al.
Published: (2014-04-01)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
by: Ghidini M, et al.
Published: (2016-06-01)

The risk factors for febrile neutropenia during chemotherapy in children with malignancy
by: Rini Sulviani, et al.
Published: (2007-05-01)

Antifungal Prophylaxis in Solid Organ Transplant Recipients
by: Şebnem ŞENOL, et al.
Published: (2015-12-01)

Multiday corticosteroids in cancer chemotherapy delay the diagnosis of and antimicrobial administration for febrile neutropenia: a double-center retrospective study
by: Hiroki Uda, et al.
Published: (2019-02-01)

History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs
by: Emmanuel Andrès, et al.
Published: (2017-09-01)

Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
by: Mingjuan Liu, et al.
Published: (2014-01-01)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
by: Sevinç A, et al.
Published: (2018-01-01)

Is preemptive antifungal therapy a good alternative to empirical treatment in prolonged febrile neutropenia?
by: Erica Koch, et al.
Published: (2016-06-01)